BioVaxys Technology Corp, a Canadian biotechnology company, has been making strides in the development of vaccines and immunotherapy products. Headquartered in Vancouver, British Columbia, the company was incorporated in 2001 and has since been a significant player in life sciences research and development. BioVaxys is dedicated to addressing global health challenges, with a particular focus on infectious diseases and cancer.
The company’s mission is to revolutionize the treatment and prevention of infectious diseases and to pioneer new immunotherapy approaches for cancer. One of its flagship products is VaxMite, a novel vaccine under development aimed at combating Plasmodium falciparum, the most lethal form of malaria. This initiative underscores BioVaxys’s commitment to tackling some of the world’s most pressing health issues.
In addition to VaxMite, BioVaxys is exploring the potential applications of its technology platform across various medical and healthcare domains. This exploration is part of the company’s broader strategy to leverage its innovative solutions to address diverse health challenges.
Financially, BioVaxys Technology Corp is listed on the Canadian National Stock Exchange, with its shares priced at CAD 0.05 as of April 16, 2026. The company’s market capitalization stands at 2,032,708 CAD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 0.45 CAD on April 22, 2025, and a low of 0.03 CAD on April 12, 2026. The price-to-earnings ratio is currently -1.2, reflecting the company’s ongoing investment in research and development, which may not yet be reflected in earnings.
BioVaxys’s focus on innovative solutions and its commitment to addressing critical health challenges position it as a key player in the biotechnology sector. As the company continues to develop its vaccine and immunotherapy products, it remains dedicated to transforming global health outcomes.
